# University of New Mexico Launches Contingency Management Program Addressing Stimulant Use Among Methadone Patients - Published: 2026-11-11 - Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md) - Topics: [News](https://healthcarenews.io/news.md) - Source: https://healthcarenews.io/news/university-of-new-mexico-launches-contingency-management-program-addressing-stimulant-use/ - Publication: Healthcare News - Publisher: Connectively (Terkel, Inc.) - Editorial policy: https://healthcarenews.io/editorial-policy/ [![CMI Logo](https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24539771-cmi-logo-300x133.jpeg "Stimulant use, including methamphetamine and cocaine, presents a serious and growing challenge for people receiving methadone treatment for opioid use disorder")](https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24539771-cmi-logo-1650x732.jpeg#1650x732) CMI Logo [![Steven Jenkins, CEO and Founder](https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24842713-steven-jenkins-300x300.jpeg)](https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24842713-steven-jenkins-400x400.jpeg#400x400) Steven Jenkins, CEO & Founder [![Addiction Freedom](https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24822518-addiction-freedom-300x200.jpeg)](https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24822518-addiction-freedom-2121x1414.jpeg#2121x1414) Addiction Freedom *12-week program at Albuquerque opioid treatment program supports patients receiving care for stimulant use supported by Contingency Management Innovations (CMI)* **“People receiving methadone treatment should be able to access evidence-based support for stimulant use as part of the care. COMPASS brings contingency management into the opioid treatment program.”** — — Kimberly A. Page, PhD, MPH, Professor, New Mexico School of Medicine SANTA MONICA, CA, UNITED STATES, November 11, 2026 /[EINPresswire.com](https://www.einpresswire.com/)/ -- Stimulant use, including methamphetamine and cocaine, presents a serious and growing challenge for people receiving methadone treatment for opioid use disorder. Methadone addresses opioid dependence, but patients may also need support for stimulant use within the same course of care. COMPASS (Contingency-based Outcomes for Methamphetamine and Polysubstance Support), led by the University of New Mexico School of Medicine, brings [contingency management](http://Contingency-management.com) into an Albuquerque opioid treatment program to address this gap. Contingency management (CM) is an evidence-based behavioral intervention for stimulant use that reinforces progress toward treatment goals. In COMPASS, participants can receive escalating incentives for stimulant-negative urine drug tests over 12 weeks. Integrating CM into methadone care matters because patients can access support for stimulant use where they already receive treatment, with fewer barriers to coordinating a separate service and better connection among their care team. COMPASS staff work directly alongside clinical teams at MedMark Five Points opioid treatment program in Albuquerque, integrating participant referrals, testing, and incentive administration into the clinic's established treatment workflows. This approach makes contingency management more accessible to patients while supporting coordination between academic researchers, treatment providers, counselors, and program staff. “People receiving methadone treatment should be able to access practical, evidence-based support for stimulant use as part of the care they are already receiving. COMPASS brings contingency management into the opioid treatment program and builds on the partnership between patients, clinicians and program staff.” — Kimberly A. Page, PhD, MPH, Professor, Department of Internal Medicine, Division of Epidemiology, Biostatistics and Preventive Medicine, University of New Mexico School of Medicine Contingency Management Innovations (CMI), which supports COMPASS, delivers a purpose-built technology platform for evidence-based contingency management programs. The platform helps organizations implement, manage and scale CM with fidelity, while supporting clinic teams with program administration, urine toxicology (UTOX) result capture, participant progress tracking, awards and incentive delivery. Across its customers CMI reports that its platform supports: • More than 15,000 patients / beneficiaries • Over 140 clinics supported • More than 310,000 toxicology results captured • Over 300,000 awards achieved • and over $4.6 million in incentives earned and distributed. "We're delighted to support the University of New Mexico and the COMPASS team in bringing contingency management into everyday clinical practice. This collaboration demonstrates how evidence-based interventions, supported by purpose-built technology, can be integrated into existing treatment services and made more accessible to patients who can benefit from them." — [Steve Jenkins](https://www.linkedin.com/in/steven-jenkins-q2i/), Chief Executive Officer of Contingency Management Innovations. ### About the University of New Mexico The University of New Mexico (UNM) is New Mexico’s flagship institution of higher education. Through its academic, research and health sciences programs, UNM works with communities across the state to advance education, discovery and health. About Contingency Management Innovations (CMI) CMI delivers purpose-built contingency management technology platform developed specifically for evidence-based incentive programs, enabling organizations to implement, manage, and scale CM with confidence, fidelity, and measurable outcomes. Backed by NIH-funded research and proven in statewide Medicaid programs, CMI reduces administrative burden, ensures compliance, and helps providers improve patient engagement, retention, and recovery outcomes. See Contingency-Management.com Media Contact Contingency Management Innovations [Larry Klimczyk](https://www.linkedin.com/in/larryklimczyk/), Chief Commercial Officer Larry@contingency-management.com Larry Klimczyk Contingency Managent Innovations [+1 9703932275]() [Larry@contingency-management.com](mailto:Larry@contingency-management.com) Visit us on social media: [LinkedIn](https://www.linkedin.com/company/contingency-management-innovations/?viewAsMember=true) [YouTube](https://www.youtube.com/@ContingencyManagement) Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. ![](https://www.einpresswire.com/tracking/article.gif?aid=955916845§ion=einpresswire&a=85K9162lTkXJ1BRN&r=Ohkp76qG8AiWTQ6s&i=Tb-1SZGp0cR00J1c) ## Related - [Medicare counted 6,436 surgery centers in 2024. Trimedx now offers them equipment maintenance nationwide](https://healthcarenews.io/news/surgery-center-equipment-maintenance-trimedx-nationwide.md) - [Novartis again leads drugmakers on reaching patients in poorer countries in the 2026 Access to Medicine Index](https://healthcarenews.io/news/2026-access-to-medicine-index-novartis-ranks-first.md) - [Glanzmann thrombasthenia has no approved preventive treatment. A weekly injection enters its final-stage trial](https://healthcarenews.io/news/glanzmann-thrombasthenia-treatment-weekly-injection-phase-3.md) - [Lupus patients reached remission on an off-the-shelf CAR-T given without chemotherapy first, Fate reports](https://healthcarenews.io/news/car-t-therapy-for-lupus-without-chemo.md)